GRANULOMATOSIS WITH POLYANGIITIS, WHICH IS PATHOGENETICALLY ASSOCIATED WITH ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES: CLINICAL FEATURES
https://doi.org/10.14412/1995-4484-2012-1288
Abstract
The author studied in detail the specific features of the clinical manifestations reflecting a granulomatous inflammatory response and necrotizing polyangiitis, by using her experience in following up 70 patients with granulomatosis and polyangiitis (Wegener's), and analyzed their early symptoms, premorbid background, and possible predictors. Granulomatous inflammation and its related clinical manifestations (primarily orbital pseudotumor and subfold granuloma of the larynx) was demonstrated to tend over time to occupy a dominant place in the clinical picture of the disease while the proportion of the symptoms apparently related to necrotizing vasculitis was generally decreased. Interpretation of mechanisms for the development of granulomatosis with polyangiitis (Wegener's) may be of value for the further elaboration of an optimal treatment strategy.
References
1. <div><p>Falk R., Gross W., Guillevin L. et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. A joint proposal of the American College of Rheumatology, the American Society of Nephrology, and the European League against Rheumatism. Arthr Rheum 2011; 63: 863-4.</p><p>Семенкова Е.Н. Системные некротизирующие васкулиты. М.: Русский врач, 2001; 96 с.</p><p>Hoffman G., Kerr G., Leavitt R. et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.</p><p>Watts R., Lane S., Hanslik T. et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66: 222—7.</p><p>Jose R., Dilworth J., Cleverley J. et al. Wegener's granulomatosis with multiple pulmonary nodules — diagnostic difficulties. J R Soc Med Short Rep 2010; 1: 34.</p><p>Falk R., Jennette J. Тhought about the classification of small vessel vasculitis. J Nephrol 2004; 17: 3—9.</p><p>Luqmani R., Bacon P., Moots R. et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671—8.</p><p>Pierrot-Deseilligny Despujol C., Pouchot J., Pagnoux C. et al. Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. Rheumatology 2010; 49: 2181—90.</p><p>Holl-Ulrich K., Reinhold-Keller E., Müller A., Feller A. Pathology of vasculitis: differential diagnosis and selected disorders. Verh Dtsch Ges Path 2002; 86: 83—90.</p><p>Witko-Sarsat V., Daniel S., Noël L., Mouthon L. Neutrophils and B lymphocytes in ANCA associated vasculitis. APMIS 2009; 117: 27—33.</p><p>Preston G., Yang J., Xiao H., Falk R. Understanding the pathogenesis of ANCA: Where are we today? Cleve Clin J Med 2002; 69: 51—4.</p><p>Lamprecht P., Gross W. Current knowledge on cellular interactions in the WG-granuloma. Clin Exp Rheumatol 2007; 25: 49—51.</p><p>Mark E., Matsubara O., Xan-Liu N., Fienberg R. The pulmonary biopsy in the early diagnosis of Wegener's (pathergic) granulematosis: a study based on 35 open lung biopsies. Hum Pathol 1988; 19: 1065—71.</p><p>Capraru D., Mü ller A., Csernok E. et al. Expansion of circulating NKG2D effector memory X cells and expression of NKG2D ligand MIC in granulomatous lesions in Wegener's granulomatosis. Clin Immunol 2008; 127: 144—50.</p><p>Raulet D. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3: 781—90.</p><p>Hua F., Wilde B., Dolff S., Witzke O. T-lymphocytes and disease mechanisms in Wegener's granulomatosis. Kidney Blood Press Res 2009; 32: 389—98.</p><p>Lamprecht P., Holle J., Gross W. Update on clinical, pathophysiological and therapeutic aspects in ANCA associated vasculitides. Curr Drug Discovery Technol 2009; 6: 241—51.</p><p>Aries P., Lamprecht P., Gross W. Wegener's Granulomatosis: A view from the granulomatous side of the disease. IMAJ 2005; 7: 768—73.</p><p>Voswinkel J., Mueller A., Kraemer J. et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006; 65: 859—64.</p><p>Baltaro R., Hoffman G., Sechler J. et al. Immunoglobulin G antineutrophil cytoplasmic antibodies are produced in the respiratory tract of patients with Wegener's granulomatosis. Am Rev Respir Dis 1991; 143: 275—8.</p><p>Krämer J., Mü ller A., Herlyn K. et al. B-Lymphozyten-Differenzierung in granulomatö sen Geweben der Lunge und der Nasenschleimhä ute beim Morbus Wegener Ursprungsort der ANCA-Bildung? Z Rheumatol 2007; 66: 421—9.</p><p>Müller A., Holl-Ulrich K., Lamprecht P., Gross W.L. Germinal centre-like structures in Wegener's granulomatosis: The morphological basis for autoimmunity? Rheumatology 2008; 47: 1111—3.</p><p>Weyand C., Seyler T., Goronzy J. B cells in rheumatoid synovitis. Arthr Res 2005; 7: 9—12.</p><p>Drayton D., Liao S., Mounzer R., Ruddle N. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006; 7: 344—53.</p><p>Hurtado P., Jeffs L., Nitschke J. et al. CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis. BMC Immunol 2008; 9: 34.</p><p>Тadema H., Abdulahad W., Lepse N. et al. CpG triggers ANCA production by bloodderived B-cells from ANCA-associated vasculitis patients in clinical remission. APMIS 2009; 117: 116.</p><p>Stegeman C., Tervaert J., Sluiter W. et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12—7.</p><p>Popa E., Stegeman C., Abdulahad W. et al. Staphylococcal toxic-shocksyndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology 2007; 46: 1029—33.</p><p>Kobayashi O., Ohtami H., Hellmich B. Anti-MPO-ANCA-positive microscopic polyangiitis following subacute bacterial endocarditis. J Infect Chem 2001; 7: 228—38.</p><p>Tiliakos A., Tiliakos N. Dual ANCA positivity in subacute bacterial endocarditis. J Clin Rheumatol 2008; 14: 38—40.</p><p>Medina F., Camargo A., Moreno J., Zonana-Nacach A. et al. Anti-neutrophil cytoplasmic autoantibodies in leprosy. Br J Rheumatol 1998; 37: 270—3.</p><p>Flores-Suarez L., Cabiedes J., Villa A. et al. Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis. Rheumatology 2003; 42: 223—9.</p><p>De Rosa F., Amoroso A., Тeggi A. et al. Anti-neutrophil cytoplasmic antibodies in echinococcus granulosus hydatid disease. Hum Immunol 2001; 62: 1122—6.</p><p>Lamprecht P., Gutzeit O., Csernok E. et al. Prevalence of ANCA in mixed cryoglobulinemia and chronic hepatitis C virus infection. Clin Exp Rheumatol 2003; 21: S89—S94.</p><p>Hermann J., Demel U., Stunzner D. et al. Clinical interpretation of antineutrophil cytoplasmic antibodies: parvovirus B19 infection as a pitfall. Ann Rheum Dis 2005; 64: 641—3.</p><p>Lanham J., Elkon K., Pusey C., Hughes G. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine 1984; 63: 65—81.</p><p>Douglas G., Bird K., Flume P. et al. Wegener's granulomatosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 2064—9.</p><p>Allen S., Harvey C. Imaging of Wegener's granulomatosis. Br J Radiol 2007; 80: 757—65.</p><p>Lohrmann C., Uhl M., Kotter E. et al. Pulmonary manifestations of Wegener granulomatosis: CТ findings in 57 patients and review of the literature. Eur J Radiol 2005; 53: 471—7.</p><p>Zycinska K., Wardyn K., Тyszko P., Otto M. Analysis of early death based on the prediction model in Wegener's granulomatosis with pulmonary and renal involvement. J Physiol Pharmacol 2007; 58: 829—37.</p><p>Bosch X. Microscopic polyangiitis (microscopic polyarteritis) with late emergence of generalised Wegener's granulomatosis. Ann Rheum Dis 1999; 58: 644—7.</p><p>Wiik A. Clinical and pathophysiological significance of anti-neutrophil cytoplasmic autoantibodies in vasculitis syndromes. Mod Rheumatol 2009; 19: 590—9.</p><p>Jayne D., Gaskin G., Pusey C., Lockwood C.M. ANCA and predicting relapse in systemic vasculitis. Q J Med 1995; 88: 127—33.</p><p>Hogan S., Falk R., Chin H. et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143: 621—31.</p><p>Bacon P. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005; 352: 330—2.</p><p>O'Connor B., Gleeson M., Noelle R., Erickson L. The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. Immunol Rev 2003; 194: 61—76.</p><p>Hoyer B., Moser K., Hauser A. et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004; 199: 1577—84.</p><p>Holle J., Dubrau C., Herlyn K. et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2012; 71: 327—33.</p><p>Falk R., Gross W., Guillevin L. et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. A joint proposal of the American College of Rheumatology, the American Society of Nephrology, and the European League against Rheumatism. Arthr Rheum 2011; 63: 863—4.</p></div><br />
Review
For citations:
Beketova T.V. GRANULOMATOSIS WITH POLYANGIITIS, WHICH IS PATHOGENETICALLY ASSOCIATED WITH ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES: CLINICAL FEATURES. Rheumatology Science and Practice. 2012;50(6):19-28. (In Russ.) https://doi.org/10.14412/1995-4484-2012-1288
Views:
1818
Email this article 